An interventional study of Prebiotic fibre blend and Maltodextrin (Placebo) in Stress, sponsored by Myota GmbH. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Myota GmbH · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This clinical trial will investigate whether a powdered prebiotic fibre blend, at two doses, can improve perceived stress levels in healthy adults with mild-severe stress levels.
There is growing interest in how the gut microbiota interacts with the brain to influence psychological outcomes, particularly stress. Even in otherwise healthy individuals, persistent psychological stress is associated with measurable physiological changes-including elevated cortisol levels, heightened hypothalamic-pituitary-adrenal (HPA) axis reactivity, and systemic low-grade inflammation. These biological signatures are increasingly understood to be shaped, in part, by the composition and activity of the gut microbiota.
This study will investigate how a powdered prebiotic fibre supplement can affect stress levels. Secondary endpoints include the effects that the prebiotic fibre supplement will have on other areas of health, like depression, mood, anxiety, cognition, inflammation, and the gut microbiome.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
This study's planned enrollment of 120 is above the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →Myota GmbH is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prebiotic fibre blend, consisting of 6g of a powdered supplement, to be taken daily alongside usual
Dietary Supplement: Prebiotic fibre blend
Prebiotic fibre blend, consisting of 10g of a powdered supplement, to be taken daily alongside usual diet for 12 weeks.
Dietary Supplement: Prebiotic fibre blend
Placebo will be 10g of maltodextrin powder, to be taken daily alongside usual diet for 12 weeks.
Dietary Supplement: Maltodextrin (Placebo)
A blend of prebiotic fibres in a powdered supplement form.
Maltodextrin powder
Perceived Stress
The primary objective is to determine the effect of 12-week long daily administration of Prebiotic fibre blend as compared to Placebo on stress scores (Perceived Stress Scale) on a scale between 0 - 40 (where higher scores indicate higher stress).
Time frame: Baseline and 12 weeks
Perceived Stress
To determine the effect of 12-week long daily administration of Prebiotic fibre blend as compared to Placebo on stress scores (Perceived Stress Scale) on a scale between 0 - 40 (where higher scores indicate higher stress).
Time frame: Baseline and 8 weeks
Depression
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on depression scores (PHQ-8), on a scale between 0 - 24 (where higher scores mean higher depression).
Time frame: Baseline, 8 weeks and 12 weeks
Mood
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on mood scores (PANAS-X), on a scale between 10 - 50 (where higher scores on the Positive Affect scale indicate higher levels of positive engagement with your environment; while higher scores on the Negative Affect scale indicate higher levels of negative engagement).
Time frame: Baseline, 8 weeks and 12 weeks
Anxiety
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on anxiety scores (GAD-7), on a scale between 0 - 21 (where higher scores mean higher anxiety levels).
Time frame: Baseline, Week 8, and Week 12
Serum hs-CRP
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum high sensitivity C-Reactive Protein (hs-CRP).
Time frame: Baseline and Week 12
Cognition: Auditory Verbal Learning Task (AVLT)
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on immediate and delayed word recognition, as assessed by the AVLT where better scores are achieved by higher number or recalled words and lower error rate.
Time frame: Baseline and Week 12
Cognition: Affective 2-Back Task
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on emotional interference in working memory under emotional load, as assessed by the Affective 2-Back Task, where better scores are achieved by lower reaction times and higher accuracy score.
Time frame: Baseline and Week 12
Cognition: Emotional Go/No-Go
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on emotion-related inhibitory control and response suppression, as assessed by the Emotional Go-No-Go, where better scores are achieved by higher correct response rates and lower commission errors.
Time frame: Baseline and Week 12
Cognition: Attentional Network Task (ANT)
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on efficiency of alerting, orienting, and executive attention networks, as assessed by the Attentional Network Task, where better scores are achieved by lower reaction times and higher accuracy.
Time frame: Baseline and Week 12
Cognition: Number Letter Task
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on cognitive flexibility and task-switching ability, as assessed by the Number Letter Task where better scores are achieved by a higher accuracy of recalled sequences.
Time frame: Baseline and Week 12
Gastrointestinal symptoms
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on gastrointestinal symptoms (GSRS), on a scale of 15 - 105 where higher scores indicate more severe gastrointestinal discomfort.
Time frame: Baseline, Week 8 and Week 12
Exploratory: Sleep quality
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on sleep quality (PSQI), on a scale of 0 - 21 where higher scores indicate worse sleep.
Time frame: Baseline and Week 12
Exploratory: Quality of Life Index
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on quality of life index (WHOQOL), on a scale of 0 -100 where higher scores indicate higher quality of life.
Time frame: Baseline And Week 12
Exploratory: Serum LDL Cholesterol
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum LDL cholesterol.
Time frame: Baseline and Week 12
Exploratory: Serum HDL Cholesterol
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum HDL cholesterol.
Time frame: Baseline and Week 12
Exploratory: Serum Triglycerides
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum triglycerides.
Time frame: Baseline and Week 12
Exploratory: Total cholesterol
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on serum total cholesterol.
Time frame: Baseline and Week 12
Exploratory: Waist to hip ratio
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on waist to hip ratio.
Time frame: Baseline and Week 12
Exploratory: Waist circumference
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on waist circumference (cm).
Time frame: Baseline and Week 12
Exploratory: Gut microbiome composition
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on gut microbiome diversity scores (alpha and beta measures) and composition (differential abundance testing).
Time frame: Baseline and Week 12
Exploratory: Systolic blood pressure
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on systolic blood pressure (mmHg).
Time frame: Baseline and Week 12
Exploratory: Diastolic blood pressure
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on diastolic blood pressure (mmHg).
Time frame: Baseline and Week 12
Exploratory: BMI
To determine the effect of 12-week daily administration of Prebiotic fibre blend as compared to Placebo on body mass index (BMI) (kg/m2).
Time frame: Baseline and Week 12
Exploratory: Perceived Stress (follow-up)
To determine the follow-up (week 16) effects of Prebiotic fibre blend, as compared to Placebo, on stress scores (PSS) on a scale between 0 - 40 (where higher scores indicate higher stress).
Time frame: Week 12 and Week 16
Exploratory: Depression (follow-up)
To determine the follow-up (week 16) effects of Prebiotic fibre blend, as compared to Placebo, on depression scores (PHQ-8) on a scale between 0 - 24 (where higher scores indicate higher stress).
Time frame: Week 12, and Week 16
Exploratory: Mood (follow-up)
To determine the follow-up (week 16) effects of Prebiotic fibre blend, as compared to Placebo, on mood scores (PANAS-X) on a scale between 10 - 50 (where higher scores on the Positive Affect scale indicate higher levels of positive engagement with your environment; while higher scores on the Negative Affect scale indicate higher levels of negative engagement).
Time frame: Week 12 and Week 16
Exploratory: Anxiety (follow-up)
To determine the follow-up (week 16) effects of Prebiotic fibre blend, as compared to Placebo, on anxiety scores (GAD-7) on a scale between 0 - 21 (where higher scores mean higher anxiety levels).
Time frame: Week 12 and Week 16
Plan to share: No — Participant data will not be shared.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.
Of 105 industry-sponsored interventional studies with no phase under Anxiety Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 16. This study's planned 19 months is above that.
Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Myota GmbH